The incidence of lymphedema in the GLP-1 RA group without diabetes was 7.1% (n = 4), and in the non-GLP-1 RA treated group without diabetes was 28.2% (n = 997) with a mean follow-up period of 66.6 ± 33.0 and 75.0 ± 37.2 months, respectively. This evidence concerns the gene GLP1R and lymphedema.